The Bone Morphogenesis Protein-2 (BMP-2) is Associated with Progression to Metastatic Disease in Gastric Cancer.
- Author:
Yong PARK
1
;
Jee Won KIM
;
Dae Sik KIM
;
Eui Bae KIM
;
Se Jong PARK
;
Jin Yong PARK
;
Woo Suk CHOI
;
Jong Gyu SONG
;
Hee Yun SEO
;
Sang Cheul OH
;
Byung Soo KIM
;
Jong Jae PARK
;
Yeul Hong KIM
;
Jun Suk KIM
Author Information
1. Department of Internal Medicine, College of Medicine, Korea University, Seoul, Korea. jskimdr@ naver.com
- Publication Type:Original Article
- Keywords:
Bone morphogenesis protein-2;
BMP-2;
Stomach neoplasms;
Invasion;
Neoplasm metastasis
- MeSH:
Bone Morphogenetic Proteins;
Cell Line;
Cell Transformation, Neoplastic;
Enzyme-Linked Immunosorbent Assay;
Humans;
Lymph Nodes;
Morphogenesis;
Neoplasm Metastasis;
Stomach Neoplasms;
Transforming Growth Factor beta
- From:Cancer Research and Treatment
2008;40(3):127-132
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Bone Morphogenetic Proteins (BMPs) are members of the TGF-beta superfamily and it has been demonstrated that BMPs enhance migration, invasion and metastasis. The purpose of this study was to identify the association between the serum BMP-2 level and the progression status of gastric cancer. MATERIALS AND METHODS: Fifty-five patients with metastatic gastric cancer (metastatic disease group), six patients with early gastric cancer without lymph node metastasis (the EGC group), and ten healthy control subjects were enrolled in this study. The serum BMP-2 level was quantified by use of a commercially available ELISA kit. In EGC group patients and patients with metastatic disease, whole blood was obtained before endoscopic mucosal resection and before the commencement of a scheduled cycle of systemic chemotherapy, respectively. RESULTS: No significant difference in the mean serum BMP-2 levels was observed between the control subjects and the EGC group patients (87.95 pg/ml for the control subjects and 84.50 pg/ml for the EGC group, p=1.0). However, the metastatic disease group patients had a significantly higher level of serum BMP (179.61 pg/ml) than the control subjects and EGC group patients (87.95 pg/ml for the control subjects and 84.50 pg/ml for the EGC group, p<0.0001). Moreover, the mean serum BMP-2 level from patients with a bone metastasis was significantly higher than the mean serum BMP-2 level from patients without a bone metastasis (204.73 pg/ml versus 173.33 pg/ml, p=0.021). CONCLUSIONS: BMP-2 seems to have a role in progression to metastatic disease in gastric cancer, especially in the late stage of tumorigenesis, including invasion and metastasis. BMP-2 may facilitate bone metastasis in gastric cancer. To confirm these findings, further studies are required with tissue specimens and the use of a cancer cell line.
